NR3C1 and plasma cell myeloma: This discrepancy may be due to the difference in assay conditions, as NanoBiT relies on overexpression of GR and MR and works in HEK293T kidney cells, while the co-IPs were performed in an endogenous context in myeloma cells where the levels of GR outweigh those of MR, as also shown in primary myeloma cells (Fig. 4N).